Manchester Airport sees a busy sequence of heavy jet action with an Airbus A380, go-arounds, VOR approaches, and sunset arrivals creating a tense aviation mix. The changing light and approach traffic ...

Git isn't hard to learn, and when you combine Git and GitHub, you've just made the learning process significantly easier. This two-hour Git and GitHub video tutorial shows you how to get started with ...

I’ve been wearing Salomons on and off since I was a teen, but as my most recent pair of basic black XT Wings nears their end (after an impressive six-year run), I’m ready to move on. After considering ...

In December, Howard Marks published an investment memo titled, “Is it a bubble?” that expressed some of his skepticism and reservations about artificial intelligence and the stock-market boom it had ...

Howard Marks is much less skeptical about AI than he was just a few months ago. In December, Howard Marks published an investment memo titled, "Is it a bubble?" that expressed some of his skepticism ...

Vor Biopharma Inc. (VOR) stock jumped to a high of $12 yesterday, gaining >20%, but as I discovered to my detriment recently, all is not exactly what it seems at the company. In this post I revisit a ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Dallan Murray joins a C-suite that Vor Bio has rebuilt quickly in recent months to support a sharp change in direction. (Nuthawut Somsuk/Getty Images) Vor Bio has handed Dallan Murray a swift return ...

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset ...

Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private placement in public equity financing and ...